HealthTech Alpha, a Galen Growth proprietary solution, powers this report!

Key Insights

• Oncology ventures dominated digital health landscape, raised significant funding, formed partnerships over 5 years.
• Funding for Oncology ventures in Q1 2023 decreased by 88% YoY. Neurology took top spot.
• Partnership activity remains strong, especially in Medical Diagnostics cluster.
• Regulatory filings for Oncology ventures stable from 2021 to 2022, indicating healthy ecosystem. Many secured funding in past 18 months and well-positioned to weather potential VC drought this year.

About our Premium Reports

Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.

Source of Data

HealthTech Alpha, Galen Growth’s proprietary platform, is the data source for this report. HealthTech Alpha is the world’s most-trusted Digital Health data, intel, and insights platform, preferred by corporate Business Development, Business Intelligence, and Digital Health Partnership teams worldwide. To find out more about our data, visit https://www.healthtechalpha.com/, or visit https://www.galengrowth.com/research for our reports.

Our Mission

Founded in 2016 by Digital Health experts, Galen Growth empowers global Fortune 500 companies, institutional investors, and promising Digital Health ventures to fast track their digital health strategy to create significant financial and social values. To find out more, visit https://www.galengrowth.com/